ST. LOUIS and ROUEN, France, July 9, 2026
Stereotaxis announced the successful completion of its previously announced acquisition of Robocath, marking a significant milestone in the advancement of robotic technologies for minimally invasive endovascular interventions. The acquisition brings together two pioneers in medical robotics, combining complementary expertise and innovative technologies to strengthen the development of next-generation robotic solutions for electrophysiology, interventional cardiology, and neurointerventions. By fully integrating Robocath into its operations, Stereotaxis aims to broaden its technological capabilities, expand its commercial opportunities, and reinforce its leadership position in the rapidly evolving field of robotic-assisted cardiovascular and neurovascular procedures. The strategic transaction also expands the company’s addressable market while supporting future innovation across multiple endovascular specialties.
Combined Technologies Strengthen Endovascular Robotics Platform
The integration of Robocath’s robotic technologies into the Stereotaxis platform creates a more comprehensive portfolio designed to support physicians performing a wide range of minimally invasive cardiovascular and neurovascular procedures. Robocath has developed robotic systems focused on interventional cardiology and neurointerventions, complementing Stereotaxis’ established expertise in robotic navigation for electrophysiology and endovascular interventions. The combined technology platform is expected to accelerate product development by leveraging the engineering capabilities, clinical experience, and intellectual property of both organizations. Together, the companies plan to deliver more advanced robotic systems that improve procedural precision, enhance physician control, and support safer, more efficient patient care across complex catheter-based interventions.
Leadership Highlights Strategic and Commercial Benefits
Executives from both organizations emphasized the strategic value of the acquisition and its potential to accelerate innovation. Philippe Bencteux, Founder and Chief Executive Officer of Robocath, said joining Stereotaxis creates an opportunity to combine the strengths of two pioneers in endovascular robotics, enabling faster innovation, broader global market reach, and expanded access to robotic technologies for physicians and patients worldwide. David Fischel, Chairman and Chief Executive Officer of Stereotaxis, stated that integrating Robocath’s technology and experienced team advances the company’s long-term strategy by strengthening technological leadership, creating attractive commercial synergies, expanding opportunities in new clinical markets, and supporting additional strategic growth initiatives. The acquisition reflects Stereotaxis’ continued investment in advancing robotic solutions that address evolving clinical needs across cardiovascular and neurovascular medicine.
Advertisement
Acquisition Supports Global Growth in Robotic Minimally Invasive Care
The completion of the acquisition further positions Stereotaxis as a global leader in robotic endovascular intervention, supporting its mission to develop innovative robotic systems, intelligent instruments, and integrated information technologies for modern interventional laboratories. The company’s robotic platforms have already been utilized in the treatment of more than 150,000 patients worldwide, demonstrating growing adoption of robotic-assisted procedures across the United States, Europe, Asia, and other international markets. By incorporating Robocath’s expertise in robotic catheter technologies, Stereotaxis is expected to accelerate the development of future robotic platforms capable of improving procedural accuracy, expanding access to minimally invasive therapies, enhancing operating room efficiency, and supporting the continued evolution of image-guided cardiovascular and neurovascular interventions. The acquisition represents an important step in the ongoing transformation of robotic-assisted endovascular medicine through technological innovation and global commercial expansion.
Source: Stereotaxis, press release
